-
Something wrong with this record ?
Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia
M. Šíma, P. Pokorná, J. Hartinger, O. Slanař,
Language English Country England, Great Britain
Document type Journal Article, Observational Study
NLK
CINAHL Plus with Full Text (EBSCOhost)
from 1998-02-01
Medline Complete (EBSCOhost)
from 1998-02-01
PubMed
28940525
DOI
10.1111/jcpt.12632
Knihovny.cz E-resources
- MeSH
- Asphyxia drug therapy metabolism MeSH
- Phenobarbital administration & dosage pharmacokinetics MeSH
- Gestational Age MeSH
- Humans MeSH
- Hypoxia-Ischemia, Brain drug therapy metabolism MeSH
- Infant, Newborn MeSH
- Half-Life MeSH
- Retrospective Studies MeSH
- Tissue Distribution MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Infant, Newborn MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
WHAT IS KNOWN AND OBJECTIVE: Phenobarbital is the first-line treatment of seizures in asphyxiated neonates; however, due to the high pharmacokinetic variability in this population, there is no consensus on the optimal dosage regimen. This study was conducted to identify variables that affect phenobarbital fate during routine clinical care and then to evaluate the dosage schedule that could be applied in term asphyxiated neonates with respect to achieving the target therapeutic range. METHODS: Phenobarbital pharmacokinetics was calculated based on serum concentrations measurements using one-compartmental model. Body weight, body surface area, gestational age, creatinine clearance, total bilirubin, alanine aminotransferase, aspartate aminotransferase, international normalized ratio, Apgar scores, umbilical cord arterial pH and base excess were explored as covariates in linear regression models. Based on this analysis, phenobarbital loading and maintenance dose regimen were projected. RESULTS AND DISCUSSION: In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively. The drug volume of distribution was associated with body weight, length and body surface area, whereas clearance was not in relationship with any explored features. Weight-normalized loading dose of 15 mg/kg and weight-normalized daily maintenance dose of 3 mg/kg proved to be optimal in our study population to reach phenobarbital therapeutic range. WHAT IS NEW AND CONCLUSIONS: This study presents basis for phenobarbital initial dosing in term asphyxiated neonates during first week of life. Phenobarbital weight-normalized loading dose of 15 mg/kg lead to simulated target peak concentrations in 72% of neonates, weight-normalized maintenance dose of 3 mg/kg lead to steady state within therapeutic window in the same proportion of patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033709
- 003
- CZ-PrNML
- 005
- 20181016103620.0
- 007
- ta
- 008
- 181008s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jcpt.12632 $2 doi
- 035 __
- $a (PubMed)28940525
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Šíma, M $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 245 10
- $a Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia / $c M. Šíma, P. Pokorná, J. Hartinger, O. Slanař,
- 520 9_
- $a WHAT IS KNOWN AND OBJECTIVE: Phenobarbital is the first-line treatment of seizures in asphyxiated neonates; however, due to the high pharmacokinetic variability in this population, there is no consensus on the optimal dosage regimen. This study was conducted to identify variables that affect phenobarbital fate during routine clinical care and then to evaluate the dosage schedule that could be applied in term asphyxiated neonates with respect to achieving the target therapeutic range. METHODS: Phenobarbital pharmacokinetics was calculated based on serum concentrations measurements using one-compartmental model. Body weight, body surface area, gestational age, creatinine clearance, total bilirubin, alanine aminotransferase, aspartate aminotransferase, international normalized ratio, Apgar scores, umbilical cord arterial pH and base excess were explored as covariates in linear regression models. Based on this analysis, phenobarbital loading and maintenance dose regimen were projected. RESULTS AND DISCUSSION: In the whole study population (N = 36), phenobarbital volume of distribution, clearance and half-life median (interquartile range) values were 0.49 (0.38-0.59) L/kg, 0.0045 (0.0034-0.0055) L/h/kg and 75.1 (60.2-103.3) hours, respectively. The drug volume of distribution was associated with body weight, length and body surface area, whereas clearance was not in relationship with any explored features. Weight-normalized loading dose of 15 mg/kg and weight-normalized daily maintenance dose of 3 mg/kg proved to be optimal in our study population to reach phenobarbital therapeutic range. WHAT IS NEW AND CONCLUSIONS: This study presents basis for phenobarbital initial dosing in term asphyxiated neonates during first week of life. Phenobarbital weight-normalized loading dose of 15 mg/kg lead to simulated target peak concentrations in 72% of neonates, weight-normalized maintenance dose of 3 mg/kg lead to steady state within therapeutic window in the same proportion of patients.
- 650 _2
- $a asfyxie $x farmakoterapie $x metabolismus $7 D001237
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gestační stáří $7 D005865
- 650 _2
- $a poločas $7 D006207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mozková hypoxie a ischemie $x farmakoterapie $x metabolismus $7 D020925
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a fenobarbital $x aplikace a dávkování $x farmakokinetika $7 D010634
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a tkáňová distribuce $7 D014018
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Pokorná, P $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Department of Pediatrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Intensive Care and Department of Pediatric Surgery, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
- 700 1_
- $a Hartinger, J $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Slanař, O $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00007277 $t Journal of clinical pharmacy and therapeutics $x 1365-2710 $g Roč. 43, č. 2 (2018), s. 196-201
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28940525 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181016104117 $b ABA008
- 999 __
- $a ok $b bmc $g 1340263 $s 1030703
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 43 $c 2 $d 196-201 $e 20170922 $i 1365-2710 $m Journal of clinical pharmacy and therapeutics $n J Clin Pharm Ther $x MED00007277
- LZP __
- $a Pubmed-20181008